

Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market - 2023-2031

<https://marketpublishers.com/r/G59AED1A7F7AEN.html>

Date: July 2025

Pages: 219

Price: US\$ 2,999.00 (Single User License)

ID: G59AED1A7F7AEN

Abstracts

The Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market was valued at US\$ 55.7 billion in 2023 and is anticipated to reach US\$ 140.9 billion by 2031, at a CAGR of 0.123 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market.

This report delivers a comprehensive overview of the Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market. The Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market
Scope:

By Type

IgG

IgA

IgM

By Indication

Primary Immunodeficiency Diseases

Secondary Immunoglobulin Deficiency Diseases

Immune Mediated Thrombocytopenia

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Key Players

Takeda Pharmaceutical Company Limited

CSL Behring

Grifols, S.A

Kedrion Biopharma

Octapharma AG

Biotest AG

Hualan Biological Engineering Inc

Shanghai RAAS Blood Products Co., Ltd

Beijing Tiantan Biological Products Co., Ltd

Sinopharm Group Co., Ltd

Major Highlights

This report delivers a comprehensive overview of the Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market. The Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than

offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Type
- 3.2. Snippet by Indication
- 3.3. Snippet by Distribution Channel
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Rising Prevalence of Immunodeficiency and Autoimmune Disorders
 - 4.1.1.2. XX
- 4.2. Restraints
 - 4.2.1. High Cost and Limited Availability of Plasma-Derived Products
- 4.3. Opportunity

5. IMPACT ANALYSIS

6. INDUSTRY ANALYSIS

- 6.1. Porter's Five Force Analysis
- 6.2. Supply Chain Analysis
- 6.3. Pricing Analysis
- 6.4. Regulatory Analysis

7. BY TYPE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

- 7.1.2. Market Attractiveness Index, By Type
- 7.2. IgG*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. IgA
- 7.4. IgM

8. BY INDICATION

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
 - 8.1.2. Market Attractiveness Index, By Indication
- 8.2. Primary Immunodeficiency Diseases*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Secondary Immunoglobulin Deficiency Diseases
- 8.4. Immune Mediated Thrombocytopenia
- 8.5. Others

9. BY DISTRIBUTION CHANNEL

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 9.1.2. Market Attractiveness Index, By Distribution Channel
- 9.2. Hospital Pharmacies*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Retail Pharmacies
- 9.4. Online Pharmacies

10. BY REGION

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
 - 10.2.1. Introduction
 - 10.2.2. Key Region-Specific Dynamics
 - 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.2.6.1. U.S.
 - 10.2.6.2. Canada
 - 10.2.6.3. Mexico
- 10.3. Europe
 - 10.3.1. Introduction
 - 10.3.2. Key Region-Specific Dynamics
 - 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
 - 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.3.6.1. Germany
 - 10.3.6.2. U.K.
 - 10.3.6.3. France
 - 10.3.6.4. Spain
 - 10.3.6.5. Italy
 - 10.3.6.6. Rest of Europe
- 10.4. South America
 - 10.4.1. Introduction
 - 10.4.2. Key Region-Specific Dynamics
 - 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
 - 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.4.6.1. Brazil
 - 10.4.6.2. Argentina
 - 10.4.6.3. Rest of South America
- 10.5. Asia-Pacific
 - 10.5.1. Introduction
 - 10.5.2. Key Region-Specific Dynamics
 - 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
 - 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.5.6.1. China
 - 10.5.6.2. India
 - 10.5.6.3. Japan

10.5.6.4. South Korea

10.5.6.5. Rest of Asia-Pacific

10.6. Middle East and Africa

10.6.1. Introduction

10.6.2. Key Region-Specific Dynamics

10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. COMPETITIVE LANDSCAPE

11.1. Competitive Scenario

11.2. Market Positioning/Share Analysis

11.3. Mergers and Acquisitions Analysis

12. COMPANY PROFILES

12.1. Takeda Pharmaceutical Company Limited*

12.1.1. Company Overview

12.1.2. Product Portfolio and Description

12.1.3. Financial Overview

12.1.4. Key Developments

12.2. CSL Behring

12.3. Grifols, S.A

12.4. Kedrion Biopharma

12.5. Octapharma AG

12.6. Biotest AG

12.7. Hualan Biological Engineering Inc

12.8. Shanghai RAAS Blood Products Co., Ltd

12.9. Beijing Tiantan Biological Products Co., Ltd

12.10. Sinopharm Group Co., Ltd (LIST NOT EXHAUSTIVE)

13. APPENDIX

13.1. About Us and Services

13.2. Contact Us

I would like to order

Product name: Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market - 2023-2031

Product link: <https://marketpublishers.com/r/G59AED1A7F7AEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G59AED1A7F7AEN.html>